Roche Aktie 224184 / US7711951043
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Trading-Depot | Watchlist |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Historisch | Analysen | |||||
|
09.12.2025 07:26:59
|
Roche Announces CE Mark For Its Cobas BV/CV Assay
(RTTNews) - Roche (RHHBY, RO.SW) announced the CE Mark for its cobas BV/CV assay to identify specific bacteria and yeast responsible for BV and CV in vaginal samples from symptomatic patients collected using the cobas PCR Media tube. The company said the cobas BV/CV assay delivers accurate and specific results, allowing healthcare professionals to deliver targeted therapies to patients more quickly. The cobas BV/CV assay is now available in countries accepting the CE Mark.
"The cobas BV/CV assay protects women from the risks of delayed or incorrect treatment, leading to faster relief from symptoms and a reduced likelihood of serious future complications," said Matt Sause, CEO of Roche Diagnostics.
For More Such Health News, visit rttnews.com.
Nachrichten zu Roche Holding AG Sponsored American Deposit Receipt Repr 1/2 NVTGSh
|
26.11.25 |
Roche-Aktie im Minus: Positive Studienergebnisse bei MS-Medikamenten (Dow Jones) | |
|
18.11.25 |
Roche-Aktie hebt ab: Medikament zeigt Wirksamkeit bei verschiedenen MS-Formen (Dow Jones) | |
|
17.10.25 |
Roche fordert Illumina mit neuer Gen-Sequenzierung-Technologie heraus (Dow Jones) | |
|
01.09.25 |
Roche-Aktie sinkt minimal: Roche plant Phase-3-Studie für neues Bluthochdruckmittel (Dow Jones) | |
|
24.07.25 |
Roche erwägt Direktverkauf von Medikamenten an US-Patienten (Dow Jones) | |
|
23.06.25 |
Roche-Aktie fester: Roche zeigt Erfolge bei Krebs- und Hämophilie-Therapien (finanzen.ch) | |
|
11.06.25 |
Roche-CEO: Trumps Arznei-Preis-Dekret bedroht US-Investitionen (Dow Jones) |